SCHEMBL1624075

SCHEMBL1624075

C=CC(=O)OCCOc1cccc(N(c2ccccc2)c2ccc(N(c3ccc(N(c4ccccc4)c4cccc(OCCOC(=O)C=C)c4)cc3)c3ccc(N(c4ccccc4)c4cccc(OCCOC(=O)C=C)c4)cc3)cc2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.68
KMT2A Q03164 4/20 0.42
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
ATM Q13315 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 2/20 0.40
MAPK1 P28482 1/20 0.40
MTNR1A P48039 4/20 0.40
MTNR1B P49286 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
TP53 P04637 2/20 0.38
HIF1A Q16665 2/20 0.38
HSD17B10 Q99714 1/20 0.38
MMP1 P03956 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28014806 0.93 THRB (0.64) THRBKMT2AKDM4EALDH1A1MEN1
SCHEMBL22356498 0.90 THRB (0.61) THRBKMT2AKDM4EALDH1A1MEN1
SCHEMBL25830904 0.89 THRB (0.75) THRBKMT2AKDM4EALDH1A1MEN1
SCHEMBL1568935 0.89 THRB (0.60) THRBKMT2AKDM4EALDH1A1MEN1
SCHEMBL14195430 0.88 THRB (0.54) THRBKMT2AALDH1A1MEN1L3MBTL1
SCHEMBL25830880 0.86 THRB (0.69) THRBKMT2AKDM4EALDH1A1MEN1
SCHEMBL12925417 0.85 THRB (0.47) THRBKMT2AKDM4EALDH1A1MEN1
SCHEMBL16625918 0.84 THRB (0.56) THRBL3MBTL1TDP1LMNAMAPK1
SCHEMBL9633402 0.83 THRB (0.78) THRBKMT2AKDM4EALDH1A1MEN1
SCHEMBL20086240 0.83 THRB (0.69) THRBKMT2AKDM4EMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2445653-B1 PAINT COATING SYSTEM AND METHOD OF PRODUCING MULTILAYERED PAINT COATING BASF SE (DE) 2016-01-06 EP disclosed
EP-2445655-B1 METHOD OF FORMING A CURED COATING COMPOSITION ON AN AUTOMOBILE COMPONENT BASF SE (DE) 2015-12-02 EP disclosed
EP-2445654-B1 METHOD OF DISSOCIATING AN ORGANOBORANE-AMINE COMPLEX BASF SE (DE) 2015-11-25 EP disclosed
US-9080000-B2 Method of forming a non-random copolymer DOW CORNING CORPORATION (US) 2015-07-14 US disclosed
EP-2393855-B1 METHOD OF FORMING A NON-RANDOM COPOLYMER DOW CORNING (US) 2015-06-17 EP disclosed
US-8927062-B2 Method of preparing a substrate with a composition including an organoborane initiator DOW CORNING CORPORATION (US) 2015-01-06 US disclosed
EP-1926602-B1 AMBIENT LITHOGRAPHIC METHOD USING ORGANOBORANE AMINE COMPLEXES DOW CORNING (US) 2014-06-18 EP disclosed
US-8734944-B2 Composite article DOW CORNING CORPORATION (US) 2014-05-27 US disclosed
US-8679585-B2 Ambient lithographic method using organoborane amine complexes DOW CORNING CORPORATION (US) 2014-03-25 US disclosed
US-8653183-B2 Method of curing a coating composition comprising a radical curable compound and an organoborane-amine complex BASF SE (DE) 2014-02-18 US disclosed
WO-2008085234-A1 PROCESS FOR FORMING FILMS AND FILMS FORMED BY THE PROCESS DOW CORNING CORPORATION (US) 2008-07-17 WO disclosed
EP-1926602-A1 AMBIENT LITHOGRAPHIC METHOD USING ORGANOBORANE AMINE COMPLEXES Dow Corning Corporation (US) 2008-06-04 EP disclosed
US-20080050552-A1 Organosilicon Functional Boron Amine Catalyst Complexes and Curable Compositions Made Therefrom DOW CORNING CORPORATION 2008-02-28 US disclosed
EP-1866344-A1 ORGANOSILLICON FUNCTIONAL BORON AMINE CATALYST COMPLEXES AND CURABLE COMPOSITIONS MADE THEREFROM Dow Corning Corporation (US) 2007-12-19 EP disclosed
WO-2007139596-A2 BORANE CATALYST COMPLEXES WITH AMIDE FUNCTIONAL POLYMERS AND CURABLE COMPOSITIONS MADE THEREFROM DOW CORNING CORPORATION (US) 2007-12-06 WO disclosed
US-20070246245-A1 Conductive Curable Compositions DOW SILICONES CORPORATION 2007-10-25 US disclosed
EP-1805256-A1 CONDUCTIVE CURABLE COMPOSITIONS Dow Corning Corporation (US) 2007-07-11 EP disclosed
WO-2007040794-A1 AMBIENT LITHOGRAPHIC METHOD USING ORGANOBORANE AMINE COMPLEXES DOW CORNING CORPORATION (US) 2007-04-12 WO disclosed
WO-2006073695-A1 ORGANOSILLICON FUNCTIONAL BORON AMINE CATALYST COMPLEXES AND CURABLE COMPOSITIONS MADE THEREFROM DOW CORNING CORPORATION (US) 2006-07-13 WO disclosed
WO-2006049792-A1 CONDUCTIVE CURABLE COMPOSITIONS DOW CORNING CORPORATION (US) 2006-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080050552-A1 Organosilicon Functional Boron Amine Catalyst Complexes and Curable Compositions Made Therefrom DBF4, MCM6, FANCF THRB 3981/4885KMT2A 1657/4885KDM4E 1235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.